Cargando…

Understanding the Role of Duration of Vaccine Protection with MenAfriVac: Simulating Alternative Vaccination Strategies

We previously developed a transmission dynamic model of Neisseria meningitidis serogroup A (NmA) with the aim of forecasting the relative benefits of different immunisation strategies with MenAfriVac. Our findings suggested that the most effective strategy in maintaining disease control was the intr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karachaliou Prasinou, Andromachi, Conlan, Andrew J. K., Trotter, Caroline L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926406/ https://www.ncbi.nlm.nih.gov/pubmed/33672209 http://dx.doi.org/10.3390/microorganisms9020461

Ejemplares similares

Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt
por: Karachaliou, Andromachi, et al.
Publicado: (2015)

MenAfriVac as an Antitetanus Vaccine
por: Borrow, Ray, et al.
Publicado: (2015)

Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials
por: Idoko, Olubukola T., et al.
Publicado: (2015)

Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali
por: Roy Chowdhury, Panchali, et al.
Publicado: (2015)

Introduction of Preventive Vaccination of Meningococcal Meningitis using MenAfriVac in Northern Uganda 2017
por: Ssewankambo, Fred
Publicado: (2017)

Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac
por: Tang, Yuxiao, et al.
Publicado: (2015)

Prevalence and epidemiology of meningococcal carriage in Southern Ethiopia prior to implementation of MenAfriVac, a conjugate vaccine
por: Bårnes, Guro K., et al.
Publicado: (2016)

Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age
por: Tapia, Milagritos D., et al.
Publicado: (2015)

Persistent low carriage of serogroup A Neisseria meningitidistwo years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac
por: Kristiansen, Paul A, et al.
Publicado: (2014)

Knowledge, beliefs and practices regarding prevention of bacterial meningitis in Burkina Faso, 5 years after MenAfriVac mass campaigns
por: Mueller, Judith E., et al.
Publicado: (2021)

Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac(®) in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa
por: Viviani, Simonetta
Publicado: (2022)

A field based evaluation of adverse events following MenAfriVac(®)vaccine delivered in a controlled temperature chain (CTC) approach in Benin
por: Steffen, Christoph, et al.
Publicado: (2014)

Evolution of meningococcal carriage in serogroups X and Y before introduction of MenAfriVac in the health district of Kaya, Burkina Faso
por: Ba, Absatou Ky, et al.
Publicado: (2014)

A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians
por: Tapia, Milagritos D., et al.
Publicado: (2015)

Bacterial meningitis epidemiology and return of Neisseria meningitidis serogroup A cases in Burkina Faso in the five years following MenAfriVac mass vaccination campaign
por: Diallo, Alpha Oumar, et al.
Publicado: (2017)

Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years
por: Diallo, Aldiouma, et al.
Publicado: (2015)

Impact of MenAfriVac on Meningococcal A Meningitis in Cameroon: A Retrospective Study Using Case-by-Case-Based Surveillance Data from 2009 to 2015
por: Gake, Bouba, et al.
Publicado: (2021)

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK
por: Hadley, Liza, et al.
Publicado: (2023)

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK – ERRATUM
por: Hadley, Liza, et al.
Publicado: (2023)

L’utilisation de l’approche CTC: quel impact sur la couverture vaccinale lors de la campagne préventive de vaccination contre la méningite A avec le MenAfriVac au Togo en 2014?
por: Landoh, Dadja Essoya, et al.
Publicado: (2017)

MODELLING THE IMPACT OF COVID-19 AND ROUTINE MENACWY VACCINATION ON MENINGOCOCCAL CARRIAGE AND DISEASE IN THE UK.
por: Hadley, L., et al.
Publicado: (2023)

Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso
por: Colombini, Anaïs, et al.
Publicado: (2015)

Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2021)

Multidisciplinary approach to genomics research in Africa: the AfriCRAN model
por: Butali, Azeez, et al.
Publicado: (2015)

VACS: VAccination disComfort Scale
por: Wallace, Manolis, et al.
Publicado: (2022)

MalVac: Database of malarial vaccine candidates
por: Chaudhuri, Rupanjali, et al.
Publicado: (2008)

Use of VacA as a Vaccine Antigen
por: Moyat, Mati, et al.
Publicado: (2016)

Modelling the cost-effectiveness of catch-up ‘MenB’ (Bexsero) vaccination in England
por: Christensen, Hannah, et al.
Publicado: (2017)

Bridging the Gap of the Afri–Eurocentric Worldview Divide in a Postcolonial South Africa
por: Johnson, Sharon, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
por: Goh, Yun Shan, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Publicado: (2023)

Minimal change disease following vaccination with CoronaVac
por: Dirim, Ahmet Burak, et al.
Publicado: (2021)

Genome stability of the vaccine strain VACΔ6
por: Maksyutov, R.A., et al.
Publicado: (2022)

Humoral responses to the CoronoVac vaccine in healthcare workers
por: Eyupoglu, Gokhan, et al.
Publicado: (2023)

ANCA-associated vasculitis following the CoronaVac vaccination
por: Ma, Yaohui, et al.
Publicado: (2022)

Afri-Can Forum 2: Johannesburg, South Africa. 16-18 February 2015
por: Mukudu, Hillary, et al.
Publicado: (2016)

Leukocytoclastic vasculitis after the third dose of CoronaVac vaccination
por: Oskay, T., et al.
Publicado: (2021)

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia
por: Tan, Cheng Siang, et al.
Publicado: (2022)

Cutaneous reactions after CoronaVac and BioNTech vaccines
por: Öner, Ümran, et al.
Publicado: (2022)

A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_prlvpr3801jg1ai3ivm11a1au2